BioSpace News Archive

TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, being held January 10-13, 2022.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference.

Alimera Sciences, Inc. announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in two investor conference events in January.

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET.

Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD).

Soleno Therapeutics, Inc. announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event.

Endotronix, Inc., today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, announced that Jennifer Lew has been appointed to its Board of Directors and will serve as chairperson of the Audit Committee.